Bas J Blaauboer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2446187/publications.pdf

Version: 2024-02-01

127	5,708	71004	93651
papers	citations	43 h-index	72 g-index

137	137	137	4900
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Toxicology Letters, 2020, 331, 259-264.	0.4	1
2	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?. Archives of Toxicology, 2020, 94, 2549-2557.	1.9	11
3	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 485-494.	1.1	8
4	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Environmental Toxicology and Pharmacology, 2020, 78, 103396.	2.0	1
5	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Food and Chemical Toxicology, 2020, 142, 111349.	1.8	1
6	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Chemico-Biological Interactions, 2020, 326, 109099.	1.7	5
7	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Toxicology in Vitro, 2020, 67, 104861.	1.1	5
8	Influence of in Vitro Assay Setup on the Apparent Cytotoxic Potency of Benzalkonium Chlorides. Chemical Research in Toxicology, 2019, 32, 1103-1114.	1.7	22
9	A mode-of-action ontology model for safety evaluation of chemicals: Outcome of a series of workshops on repeated dose toxicity. Toxicology in Vitro, 2019, 59, 44-50.	1.1	19
10	Contributions to Alternatives From The Netherlands, Belgium and France. , 2019, , 35-45.		0
11	Integrated Approaches to Testing and Assessment. , 2019, , 301-306.		1
12	A strategy for systemic toxicity assessment based on non-animal approaches: The Cosmetics Europe Long Range Science Strategy programme. Toxicology in Vitro, 2018, 50, 137-146.	1.1	40
13	Reconstructed human epidermis models for irritant testing of medical devices. Toxicology in Vitro, 2018, 50, 399-400.	1.1	3
14	CON4EI: CONsortium for in vitro Eye Irritation testing strategy. Toxicology in Vitro, 2018, 49, 1.	1.1	0
15	Alternative approaches for identifying acute systemic toxicity: Moving from research to regulatory testing. Toxicology in Vitro, 2017, 41, 245-259.	1.1	54
16	In vitro testing of basal cytotoxicity: Establishment of an adverse outcome pathway from chemical insult to cell death. Toxicology in Vitro, 2017, 39, 104-110.	1.1	64
17	Dedication to Dr J.M. ZaldÃvar Comenges (1958â€“2012). Toxicology in Vitro, 2017, 45, 207-208.	1.1	0
18	In vitro, ex vivo, in vivo toxicology, the terminology issue. Toxicology in Vitro, 2017, 45, iii-iv.	1.1	2

#	Article	IF	Citations
19	The European Registered Toxicologist (ERT): Current status and prospects for advancement. Toxicology Letters, 2016, 259, 151-155.	0.4	4
20	Considering new methodologies in strategies for safety assessment of foods and food ingredients. Food and Chemical Toxicology, 2016, 91, 19-35.	1.8	54
21	Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 343-358.	0.9	75
22	Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System. Toxicological Sciences, 2015, 146, 11-15.	1.4	30
23	Biokinetics in repeated-dosing in vitro drug toxicity studies. Toxicology in Vitro, 2015, 30, 217-224.	1.1	80
24	The Predict-IV project: Towards predictive toxicology using in vitro techniques. Toxicology in Vitro, 2015, 30, 1-3.	1.1	8
25	Stem Cell-Derived Systems in Toxicology Assessment. Stem Cells and Development, 2015, 24, 1284-1296.	1.1	49
26	Making sense of in vitro methods. Proceedings of the 18th ESTIV congress. Toxicology in Vitro, 2015, 29, 1215-1216.	1.1	0
27	Regulatory acceptance and use of the Extended One Generation Reproductive Toxicity Study within Europe. Regulatory Toxicology and Pharmacology, 2015, 71, 114-124.	1.3	5
28	Biokinetics of chlorpromazine in primary rat and human hepatocytes and human HepaRG cells after repeated exposure. Toxicology in Vitro, 2015, 30, 52-61.	1.1	21
29	Quantitative in vitro to in vivo extrapolation (QIVIVE): An essential element for in vitro-based risk assessment. Toxicology, 2015, 332, 1-3.	2.0	37
30	An alkaline phosphatase transport mechanism in the pathogenesis of Alzheimerâ€™s disease and neurodegeneration. Chemico-Biological Interactions, 2015, 226, 30-39.	1.7	19
31	Dose metric considerations in in vitro assays to improve quantitative in vitroâ€“in vivo dose extrapolations. Toxicology, 2015, 332, 30-40.	2.0	168
32	The long and winding road of progress in the use of in vitro data for risk assessment purposes: From â€œcarnation testâ€•to integrated testing strategies. Toxicology, 2015, 332, 4-7.	2.0	15
33	The in vitro biokinetics of chlorpromazine and diazepam in aggregating rat brain cell cultures after repeated exposure. Toxicology in Vitro, 2015, 30, 185-191.	1.1	4
34	Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling. Archives of Toxicology, 2015, 89, 1135-1148.	1.9	56
35	Regulatory acceptance and use of serology for inactivated veterinary rabies vaccines. ALTEX: Alternatives To Animal Experimentation, 2015, 32, 211-21.	0.9	2
36	Leukemia from Dermal Exposure to Cyclophosphamide among Nurses in the Netherlands: Quantitative Assessment of the Risk. Annals of Occupational Hygiene, 2014, 58, 271-82.	1.9	18

#	Article	IF	Citations
37	Replacing the NIH test for rabies vaccine potency testing: A synopsis of drivers and barriers. Biologicals, 2014, 42, 205-217.	0.5	22
38	Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. Toxicology in Vitro, 2014, 28, 164-170.	1.1	51
39	Excessive levels of diverse phytoestrogens can modulate steroidogenesis and cell migration of KGN human granulosa-derived tumor cells. Toxicology Reports, 2014, 1, 360-372.	1.6	21
40	Regulatory acceptance and use of 3R models for pharmaceuticals and chemicals: Expert opinions on the state of affairs and the way forward. Regulatory Toxicology and Pharmacology, 2014, 69, 41-48.	1.3	22
41	Naringenin (NAR) and 8-prenylnaringenin (8-PN) reduce the developmental competence of porcine oocytes in vitro. Reproductive Toxicology, 2014, 49, 1-11.	1.3	14
42	In Vitro Approaches to Predictive Biokinetics. Methods in Pharmacology and Toxicology, 2014, , 521-530.	0.1	0
43	A novel hypothesis for an alkaline phosphatase â€˜rescueâ€™ mechanism in the hepatic acute phase immune response. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2044-2056.	1.8	61
44	Scientifically unfounded precaution drives European Commissionâ€™s recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. Toxicology in Vitro, 2013, 27, 2110-2114.	1.1	18
45	Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. Journal of Proteomics, 2013, 79, 180-194.	1.2	168
46	Towards toxicity assessment without animals. Toxicology in Vitro, 2013, 27, 1563-1564.	1.1	0
47	Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicology in Vitro, 2013, 27, 1320-1346.	1.1	165
48	Editorial. Food and Chemical Toxicology, 2013, 62, A1-A4.	1.8	6
49	In vitro biokinetics of chlorpromazine and the influence of different dose metrics on effect concentrations for cytotoxicity in Balb/c 3T3, Caco-2 and HepaRG cell cultures. Toxicology in Vitro, 2013, 27, 1057-1064.	1.1	25
50	Sens-it-iv: A European Union project to develop novel tools for the identification of skin and respiratory sensitizers. Toxicology in Vitro, 2013, 27, 1121.	1.1	2
51	Editorial. Regulatory Toxicology and Pharmacology, 2013, 67, 317-320.	1.3	9
52	Open letter to the European commission: scientifically unfounded precaution drives European commissionâ€™s recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles. Archives of Toxicology, 2013, 87, 1739-1741.	1.9	24
53	Scientifically unfounded precaution drives European Commissionâ€™s recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. ALTEX: Alternatives To Animal Experimentation, 2013, 30, 381-385.	0.9	9
54	Quantifying Processes Determining the Free Concentration of Phenanthrene in Basal Cytotoxicity Assays. Chemical Research in Toxicology, 2012, 25, 436-445.	1.7	101

#	Article	IF	Citations
55	Transport of Chlorpromazine in the Caco-2 Cell Permeability Assay: A Kinetic Study. Chemical Research in Toxicology, 2012, 25, 1442-1451.	1.7	29
56	Towardin vitrobiomarkers for developmental toxicity and their extrapolation to thein vivosituation. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 11-27.	1.5	29
57	A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. ALTEX: Alternatives To Animal Experimentation, 2012, 29, 3-91.	0.9	190
58	Regulatory acceptance and use of 3R models: a multilevel perspective. ALTEX: Alternatives To Animal Experimentation, 2012, 29, 287-300.	0.9	29
59	The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX: Alternatives To Animal Experimentation, 2012, 29, 411-425.	0.9	87
60	Report from the EPAA workshop: In vitro ADME in safety testing used by EPAA industry sectors. Toxicology in Vitro, 2011, 25, 589-604.	1.1	30
61	Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. Regulatory Toxicology and Pharmacology, 2011, 61, 105-14.	1.3	32
62	Development of a negligible depletion-solid phase microextraction method to determine the free concentration of chlorpromazine in aqueous samples containing albumin. Journal of Chromatography A, 2011, 1218, 8529-8535.	1.8	28
63	Decrease of intracellular pH as possible mechanism of embryotoxicity of glycol ether alkoxyacetic acid metabolites. Toxicology and Applied Pharmacology, 2010, 245, 236-243.	1.3	16
64	Biokinetic Modeling andin Vitroâ€“in VivoExtrapolations. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2010, 13, 242-252.	2.9	144
65	Quantitative cytometry as a tool for toxicity assessment. Toxicology in Vitro, 2010, 24, 2059.	1.1	0
66	The Use of In Vitro Toxicity Data and Physiologically Based Kinetic Modeling to Predict Dose-Response Curves for In Vivo Developmental Toxicity of Glycol Ethers in Rat and Man. Toxicological Sciences, 2010, 118, 470-484.	1.4	110
67	Relative Developmental Toxicity of Glycol Ether Alkoxy Acid Metabolites in the Embryonic Stem Cell Test as compared with the In Vivo Potency of their Parent Compounds. Toxicological Sciences, 2009, 110, 117-124.	1.4	67
68	Editorial: Proceedings of ESTIV 2008, the 15th International Congress on In Vitro Toxicology. Toxicology in Vitro, 2009, 23, 1443-1444.	1.1	0
69	The contribution of in vitro toxicity data in hazard and risk assessment: Current limitations and future perspectives. Toxicology Letters, 2008, 180, 81-84.	0.4	48
70	On the incorporation of chemical-specific information in risk assessment. Toxicology Letters, 2008, 180, 100-109.	0.4	32
71	Optimisation of the Post-validation Process. ATLA Alternatives To Laboratory Animals, 2008, 36, 353-366.	0.7	12
72	Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity. Human and Experimental Toxicology, 2007, 26, 333-338.	1.1	64

#	Article	IF	Citations
73	Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda. ATLA Alternatives To Laboratory Animals, 2007, 35, 661-671.	0.7	59
74	The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Archives of Toxicology, 2007, 81, 385-387.	1.9	48
75	Factors stimulating or obstructing the implementation of the 3Rs in the regulatory process. ALTEX: Alternatives To Animal Experimentation, 2007, 24, 271-278.	0.9	16
76	Metabolism: A Bottleneck inIn VitroToxicological Test Development. ATLA Alternatives To Laboratory Animals, 2006, 34, 49-84.	0.7	161
77	THE USE OF SANDWICH-CULTURED RAT HEPATOCYTES TO DETERMINE THE INTRINSIC CLEARANCE OF COMPOUNDS WITH DIFFERENT EXTRACTION RATIOS: 7-ETHOXYCOUMARIN AND WARFARIN. Drug Metabolism and Disposition, 2005, 33, 1325-1332.	1.7	26
78	An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing. Regulatory Toxicology and Pharmacology, 2005, 42, 284-295.	1.3	62
79	Blood-Brain Barrier In Vitro Models and Their Application in Toxicology: The Report and Recommendations of ECVAM Workshop 49,. ATLA Alternatives To Laboratory Animals, 2004, 32, 37-50.	0.7	50
80	MODELING THE IN VITRO INTRINSIC CLEARANCE OF THE SLOWLY METABOLIZED COMPOUND TOLBUTAMIDE DETERMINED IN SANDWICH-CULTURED RAT HEPATOCYTES. Drug Metabolism and Disposition, 2004, 32, 884-891.	1.7	33
81	The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicology Letters, 2003, 138, 161-171.	0.4	59
82	Biokinetic and Toxicodynamic Modelling and its Role in Toxicological Research and Risk Assessment. ATLA Alternatives To Laboratory Animals, 2003, 31, 277-281.	0.7	19
83	The applicability of in vitro-derived data in hazard identification and characterisation of chemicals. Environmental Toxicology and Pharmacology, 2002, 11, 213-225.	2.0	34
84	Methods of in vitro toxicology. Food and Chemical Toxicology, 2002, 40, 193-236.	1.8	367
85	The Necessity of Biokinetic Information in the Interpretation of In Vitro Toxicity Data. ATLA Alternatives To Laboratory Animals, 2002, 30, 85-91.	0.7	27
86	The Prediction of Systemic Toxicity by Integrating the Results of Biokinetic Models and Biologically Based In Vitro Test Methods. , 2002, , 155-194.		0
87	Toxicodynamic modelling and the interpretation of in vitro toxicity data. Toxicology Letters, 2001, 120, 111-123.	0.4	27
88	The Integrated Use of Alternative Methods in Toxicological Risk Evaluation. ATLA Alternatives To Laboratory Animals, 1999, 27, 229-237.	0.7	64
89	An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS Project. Toxicology in Vitro, 1999, 13, 549-554.	1.1	61
90	Joint Reports 13th Meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC): Alternative Testing Methodologies and Conceptual Issues. Environmental Health Perspectives, 1998, 106, 413.	2.8	21

#	Article	IF	Citations
91	Solid Phase Microextraction as a Tool To Determine Membrane/Water Partition Coefficients and Bioavailable Concentrations inin VitroSystems. Chemical Research in Toxicology, 1997, 10, 1067-1072.	1.7	161
92	Simulation of lindane kinetics in rats. Toxicology, 1997, 122, 1-9.	2.0	11
93	Simulation of Toluene Kinetics in the Rat by a Physiologically Based Pharmacokinetic Model with Application of Biotransformation Parameters Derived Independentlyin Vitroandin Vivo. Fundamental and Applied Toxicology, 1996, 32, 260-268.	1.9	35
94	In Vitro-based and In Vivo-hased Simulations of Benzene Uptake and Metabolism in Rats. ATLA Alternatives To Laboratory Animals, 1996, 24, 179-190.	0.7	7
95	The Use of Biokinetics and in Vitro Methods in Toxicological Risk Evaluation. ATLA Alternatives To Laboratory Animals, 1996, 24, 473-497.	0.7	30
96	Interactive effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and retinoids on proliferation and differentiation in cultured human keratinocytes: quantification of cross-linked envelope formation. Archives of Toxicology, 1995, 69, 368-378.	1.9	14
97	Practical Aspects of the Validation of Toxicity Test Procedures. ATLA Alternatives To Laboratory Animals, 1995, 23, 129-146.	0.7	240
98	The Practical Applicability of Hepatocyte Cultures in Routine Testing. ATLA Alternatives To Laboratory Animals, 1994, 22, 231-241.	0.7	73
99	Applicability of cultured hepatocytes derived from goat, sheep and cattle in comparative drug metabolism studies. Xenobiotica, 1994, 24, 417-428.	0.5	17
100	Role of thiol homeostasis and adenine nucleotide metabolism in the protective effects of fructose in quinone-induced cytotoxicity in rat hepatocytes. Biochemical Pharmacology, 1994, 48, 1683-1692.	2.0	6
101	The ECITTS integrated toxicity testing scheme: The application of in vitro test systems to the hazard assessment of chemicals. Toxicology in Vitro, 1994, 8, 845-846.	1.1	20
102	Differences in the effects of model inducers of cytochrome P450 on the biotransformation of scoparone in rat and hamster liver. Archives of Toxicology, 1993, 67, 92-97.	1.9	8
103	Cytotoxicity of menadione and related quinones in freshly isolated rat hepatocytes: effects on thiol homeostasis and energy charge. Archives of Toxicology, 1993, 67, 674-679.	1.9	26
104	Effects of the peroxisome proliferator mono(2-ethylhexyl)phthalate in primary hepatocyte cultures derived from rat, guinea pig, rabbit and monkey. Biochemical Pharmacology, 1993, 45, 2425-2434.	2.0	34
105	Hepatic cytochrome P450 induction in goats. Biochemical Pharmacology, 1993, 45, 113-122.	2.0	21
106	Cytochrome P450 induction and metabolism of alkoxyresorufins, ethylmorphine and testosterone in cultured hepatocytes from goats, sheep and cattle. Biochemical Pharmacology, 1993, 46, 1781-1790.	2.0	44
107	Effect of diphenyl ether herbicides and oxadiazon on porphyrin biosynthesis in mouse liver, rat primary hepatocyte culture and HepG2 cells. Archives of Toxicology, 1993, 67, 255-261.	1.9	25
108	Effects of various medium formulations and attachment substrata on the performance of cultured ruminant hepatocytes in biotransformation studies. Xenobiotica, 1992, 22, 523-534.	0.5	33

#	Article	IF	Citations
109	Effects of indole-3-carbinol on biotransformation enzymes in the rat: in vivo changes in liver and small intestinal mucosa in comparison with primary hepatocyte cultures. Food and Chemical Toxicology, 1992, 30, 589-599.	1.8	67
110	Acid reaction products of indole-3-carbinol and their effects on cytochrome P450 and phase II enzymes in rat and monkey hepatocytes. Biochemical Pharmacology, 1992, 43, 1439-1447.	2.0	60
111	Induction of terminal differentiation in cultured human keratinocytes by polychlorinated aromatic hydrocarbons as measured by cell size analysis. Toxicology and Applied Pharmacology, 1992, 113, 240-245.	1.3	11
112	Interlaboratory comparison of microsomal ethoxyresorufin and pentoxyresorufin O-dealkylation determinations: standardization of assay conditions. Archives of Toxicology, 1992, 66, 237-244.	1.9	75
113	ECITTS: An Integrated Approach to the Application of In Vitro Test Systems to the Hazard Assessment of Chemicals,. ATLA Alternatives To Laboratory Animals, 1992, 20, 406-428.	0.7	56
114	Biotransformation of scoparone used to monitor changes in cytochrome P450 activities in primary hepatocyte cultures derived from rats, hamsters and monkeys. Biochemical Pharmacology, 1991, 41, 1203-1208.	2.0	22
115	Comparison of cytochrome P450 isoenzyme profiles in rat liver and hepatocyte cultures. Biochemical Pharmacology, 1991, 42, 381-390.	2.0	118
116	Structure elucidation of acid reaction products of indole-3-carbinol: Detection in vivo and enzyme induction in vitro. Chemico-Biological Interactions, 1991, 80, 303-315.	1.7	155
117	Immunohistochemical detection of cytochrome P450 isoenzymes in cultured human epidermal cells.. Journal of Histochemistry and Cytochemistry, 1990, 38, 1847-1851.	1.3	18
118	The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact monolayers. Biochemical Pharmacology, 1990, 40, 2525-2534.	2.0	156
119	The effect of beclobric acid and clofibric acid on peroxisomal Î²-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochemical Pharmacology, 1990, 40, 521-528.	2.0	91
120	The Use of Liver Cell Cultures Derived from Different Mammalian Species in In Vitro Toxicological Studies: Implementation in Extrapolation Models?. ATLA Alternatives To Laboratory Animals, 1990, 18, 251-258.	0.7	23
121	Application of high-performance liquid chromatographic analysis of scoparone and its metabolites in the study of cytochrome P450 differentiation in vitro. Biomedical Applications, 1989, 487, 489-495.	1.7	12
122	Effects of 1,2-dibromoethane on isolated hepatocytes: Functional alterations and induction of lipid peroxidation. Xenobiotica, 1988, 18, 675-683.	0.5	3
123	Interlaboratory comparison of total cytochrome P-450 and protein determinations in rat liver microsomes. Archives of Toxicology, 1987, 61, 27-33.	1.9	204
124	The concentration of cytochrome P-450 in human hepatocyte culture. Biochemical Pharmacology, 1985, 34, 2405-2408.	2.0	34
125	Kinetics of the formation and secretion of the aniline metabolite 4-aminophenol and its conjugates by isolated rat hepatocytes. Xenobiotica, 1984, 14, 409-416.	0.5	18
126	Formation and disposition ofN-hydroxylated metabolites of aniline and nitrobenzene by isolated rat hepatocytes. Xenobiotica, 1983, 13, 295-302.	0.5	14

#	Article	IF	Citations
127	Attachment of rat hepatocytes to plastic substrata in the absence of serum requires protein synthesis. Biochemical and Biophysical Research Communications, 1979, 90, 368-374.	1.0	26